Role of serum HER2 (sHER2) levels to predict acquisition of HER2 overexpression in patients with metastatic lesions of breast cancer with HER2-negative/unknown at the primary site

被引：1
|
作者：
Ribeiro, J. T. M. L.
Ali, S. M.
Correia, L.
Luis, I. M. V. D.
Matias, M.
Amaral, T.
Quintela, A. A. F. G.
Leitzel, K.
Lipton, A.
Costa, L.
机构：
[1] Hosp Santa Maria, Dept Oncol, Lisbon, Portugal
[2] Univ Lisbon, Inst Mol Med, P-1699 Lisbon, Portugal
[3] Lebanon VA Med Ctr, Penn State Hershey Med Ctr, Hershey, PA USA
[4] Hosp Santa Maria, Dept Pathol, Lisbon, Portugal
[5] Penn State Hershey Med Ctr, Hershey, PA USA
[6] Hosp Santa Maria, Dept Oncol, CHLN, Lisbon, Portugal
[7] IMM, Clin & Translat Oncol Res Unit, Lisbon, Portugal
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11114
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor
    Beije, Nick
    Onstenk, Wendy
    Kraan, Jaco
    Sieuwerts, Anieta M.
    Hamberg, Paul
    Dirix, Luc Y.
    Brouwer, Anja
    de Jongh, Felix E.
    Jager, Agnes
    Seynaeve, Caroline M.
    Van, Ngoc M.
    Foekens, John A.
    Martens, John W. M.
    Sleijfer, Stefan
    NEOPLASIA, 2016, 18 (11): : 647 - 653
  • [32] Monitoring serum HER2 levels in breast cancer patients
    Tchou, Julia
    Lam, Lian
    Li, Yun Rose
    Edwards, Claire
    Ky, Bonnie
    Zhang, Hongtao
    SPRINGERPLUS, 2015, 4
  • [33] Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
    Bose, Ron
    Kavuri, Shyam M.
    Searleman, Adam C.
    Shen, Wei
    Shen, Dong
    Koboldt, Daniel C.
    Monsey, John
    Goel, Nicholas
    Aronson, Adam B.
    Li, Shunqiang
    Ma, Cynthia X.
    Ding, Li
    Mardis, Elaine R.
    Ellis, Matthew J.
    CANCER DISCOVERY, 2013, 3 (02) : 224 - 237
  • [34] The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study
    Coriano, Matilde
    Tommasi, Chiara
    Dinh, Anh Thi Lan
    Needham, Jazmine
    Aziz, Hala
    Joharatnam-Hogan, Nalinie
    Cunningham, Niamh
    Waterhouse, Jasmin
    Sun, Mingze
    Turkes, Fiona
    Pellegrino, Benedetta
    Mcgrath, Sophie
    Okines, Alicia
    Parton, Marina
    Turner, Nicholas
    Johnston, Stephen
    Musolino, Antonino
    Ring, Alistair
    Battisti, Nicolo Matteo Luca
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 206 (03) : 603 - 614
  • [35] HER2 0, HER2 1+and HER2 2+/FISH Negative Primary Breast Cancers Are Biologically Distinct
    Donahue, Nolan
    Aragao, Alessa
    Gordezky, Rachel
    Haddad, Sandra
    Tang, Ping
    LABORATORY INVESTIGATION, 2024, 104 (03) : S146 - S148
  • [36] BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer
    Sampson, E. L.
    Valero, V.
    Roche, H.
    Pienkowski, T.
    Canon, J.
    Zhao, Y.
    Carney, W.
    Mackey, J.
    Taupin, H.
    Lindsay, M.
    Buyse, M.
    Slamon, D.
    CLINICAL CHEMISTRY, 2007, 53 (06) : A34 - A34
  • [37] BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer
    Valero, V.
    Roche, H.
    Pienkowski, T.
    Canon, J.
    Zhao, Y.
    Carney, W.
    Mackey, J.
    Taupin, H.
    Buyse, M.
    Slamon, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] HER2 overexpression in metastatic breast cancer: development of therapies
    Pivot, X.
    Jary, M.
    Dobi, E.
    Bazan, F.
    Chaigneau, L.
    Cals, L.
    Almotlak, H.
    Montcuquet, P.
    Meneveau, N.
    Villanueva, C.
    ONCOLOGIE, 2012, 14 (01) : 37 - 40
  • [39] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [40] Efficacy of HER2 inhibitors in metastatic breast cancer by discordance in HER2 amplification status between primary and metastatic breast cancer
    Van Raemdonck, E.
    Berteloot, P.
    Laenen, A.
    Han, S.
    Van Nieuwenhuysen, E.
    Salihi, R.
    Concin, N.
    Vergote, I.
    Floris, G.
    Wildiers, H.
    Punie, K.
    Neven, P.
    CANCER RESEARCH, 2019, 79 (04)
12345